2018, Número 4
<< Anterior Siguiente >>
Rev Hematol Mex 2018; 19 (4)
Leucemia mieloide crónica en remisión molecular mayor después de 44 meses sin tratamiento
Ron-Guerrero CS, Ron-Magaña AL
Idioma: Español
Referencias bibliográficas: 14
Paginas: 231-236
Archivo PDF: 344.57 Kb.
RESUMEN
Se comunica el caso de una paciente de 44 años de edad, con diagnóstico de leucemia
mieloide crónica desde octubre de 2006. Se calculó su índice pronóstico de Sokal y
Hasford, con resultado de bajo riesgo en ambos. La remisión hematológica se logró
en seis semanas. Recibió imatinib durante 55 meses, luego nilotinib durante 37 meses,
con un total de 92 meses de tratamiento con inhibidores de tirosina-cinasa. La paciente
permanece en remisión molecular mayor a 44 meses sin tratamiento (transcriptos
indetectables) hasta el momento de este reporte.
REFERENCIAS (EN ESTE ARTÍCULO)
O’Brien SG, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994.
Hochhaus A, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017;376:917.
Hehlmann R, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non- CML determinants. Leukemia 2017;31:2398.
Wang J, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood 2015;125:2771.
Kantarjian HM, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119:1123.
Cortes JE, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012;30:3486.
Cortes JE, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: Results from the randomized BFORE trial. J Clin Oncol 2018;36:231.
Kwak JY, et al. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clin Cancer Res 2017;23:7180.
Saussele S, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010;115:1880.
Apperley JF. TWIST it but don’t spin it. Blood 2013;122:470.
Etienne G, et al. Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia. J Clin Oncol 2017;35:298.
Ross DM, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515.
Rea D, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 2017;129:846.
Hochhaus A, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 2017;31:1525.a